FOR IMMEDIATE RELEASE

Langhorne, PA | November 25, 2024

Amplity presented findings at the Professional Society for Health Economics and Outcomes Research (ISPOR) Europe 2024 conference from a new study on real-world usage patterns of GLP-1 receptor agonist (GLP-1 RA) medications among US patients. Using the Amplity AnswerY™ (formerly Amplity Insights) real-world database, the study provides valuable insights into how GLP-1 RAs are used for diabetes, weight loss, or both across diverse patient groups.

The study examined data from January 1, 2017, to June 30, 2024, analyzing records from 94,762 patients treated with GLP-1 RAs. Advanced AI and natural language processing technology were used to identify usage patterns for specific GLP-1 RA agents, including liraglutide, dulaglutide, semaglutide, and exenatide, while excluding data on insulin-combination therapies such as SOLIQUA^® (lixisenatide and insulin glargine) due to limited data.

Key Findings on GLP-1 RA Medication Use

The analysis found that within the diabetic and nondiabetic patient groups:

• Liraglutide was the most frequently prescribed, accounting for 40.6% of GLP-1 RA prescriptions
• Dulaglutide was the second most common at 35.5%, followed by semaglutide at 15.8%, and exenatide at 10.3%
• Tirzepatide usage was notably low, seen in just 0.4% of patients overall

Distinct differences emerged between diabetic (86,140 patients) and nondiabetic (8622 patients) groups:

• Semaglutide use was higher among nondiabetic patients (25.6%) compared with diabetic patients (14.9%)
• Dulaglutide was more commonly prescribed to diabetic patients (36.4%) than to nondiabetic patients (25.7%)
• Tirzepatide was more frequently prescribed to nondiabetic patients (2.6%) than to diabetic patients (0.2%)

Findings on GLP-1 RAs for Weight Management

Although GLP-1 RA use for weight loss was limited, likely due to manufacturing constraints, distribution challenges, and insurance restrictions, Amplity Insights, soon to be known as AnswerY, anticipates increased use of GLP-1 RAs, such as tirzepatide, for weight management, especially among individuals with a BMI ≥30 kg/m² or a BMI ≥27 kg/m² with related health conditions. In general, it is expected that the increased availability of additional anti-obesity medications will provide more treatment options for patients with obesity. These findings also provide healthcare providers and policymakers with valuable data to guide decisions about patient access, insurance coverage, and treatment options for both diabetes and weight management.

About Amplity AnswerY (formerly Amplity Insights)

Disrupting Data Norms

AnswerY, our proprietary HIPAA-compliant database + platform, cuts through marketplace noise with data sourced from unfiltered patient-provider conversations. Powered by NLP + AI, AnswerY explains the “why” behind treatment rationale for improved care + smarter strategies. Exclusive intel, straight from the source.

About Amplity 

Expert-led teams that deliver.
Pharma at its best: Quicker. Better. Nicer. 

Your full-service go-to partners delivering both flexible and specialized medical and commercial services. No matter where you are in the lifecycle of your drug, we scale with ease.
Our people-driven tech-enabled DNA fuels everything we do. 

To learn more about AnswerY, please reach out to Vikram Singh, Vice President, Client Partnerships, [email protected]

To connect with Amplity’s Marketing and PR team, please email [email protected].